E-viri
Recenzirano
Odprti dostop
-
Babitt, Jodie L.; Eisenga, Michele F.; Haase, Volker H.; Kshirsagar, Abhijit V.; Levin, Adeera; Locatelli, Francesco; Małyszko, Jolanta; Swinkels, Dorine W.; Tarng, Der-Cherng; Cheung, Michael; Jadoul, Michel; Winkelmayer, Wolfgang C.; Drüeke, Tilman B.; Abu-Alfa, Ali K.; Afsar, Baris; Pai, Amy Barton; Besarab, Anatole; Moore, Geraldine Biddle; Casadevall, Nicole; Cases, Aleix; de Francisco, Angel; Eckardt, Kai-Uwe; Fishbane, Steven; Fried, Linda F.; Ganz, Tomas; Ginzburg, Yelena Z.; Gómez, Rafael; Goodnough, Lawrence T.; Hamano, Takayuki; Hanudel, Mark R.; Hao, Chuan-Ming; Iseki, Kunitoshi; Ix, Joachim H.; Johansen, Kirsten L.; Ketteler, Markus; Kovesdy, Csaba P.; Leaf, David E.; Macdougall, Iain C.; Massy, Ziad A.; McMahon, Lawrence P.; Minutolo, Roberto; Nakanishi, Takeshi; Nemeth, Elizabeta; Obrador, Gregorio T.; Parfrey, Patrick S.; Park, Hyeong-Cheon; Pecoits-Filho, Roberto; Robinson, Bruce M.; Roger, Simon D.; Shah, Yatrik M.; Spinowitz, Bruce S.; Tanaka, Tetsuhiro; Tsukamoto, Yusuke; Tungsanga, Kriang; Walther, Carl P.; Yee-Moon Wang, Angela; Wolf, Myles
Kidney international, 06/2021, Letnik: 99, Številka: 6Journal Article
In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluation, and treatment of anemia in chronic kidney disease. Since then, new data have accrued from basic research, epidemiological studies, and randomized trials that warrant a re-examination of previous recommendations. Therefore, in 2019, KDIGO decided to convene 2 Controversies Conferences to review the latest evidence, explore new and ongoing controversies, assess change implications for the current KDIGO anemia guideline, and propose a research agenda. The first conference, described here, focused mainly on iron-related issues, including the contribution of disordered iron homeostasis to the anemia of chronic kidney disease, diagnostic challenges, available and emerging iron therapies, treatment targets, and patient outcomes. The second conference will discuss issues more specifically related to erythropoiesis-stimulating agents, including epoetins, and hypoxia-inducible factor-prolyl hydroxylase inhibitors. Here we provide a concise overview of the consensus points and controversies resulting from the first conference and prioritize key questions that need to be answered by future research.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.